A phase I/II study of nivolumab, paclitaxel, and ramucirumab as second-line in advanced gastric cancer

被引：0
|
作者：
Hironaka, Shuichi
Kadowaki, Shigenori
Izawa, Naoki
Nishina, Tomohiro
Yamanaka, Takeharu
Minashi, Keiko
Muro, Kei
Sunakawa, Yu
Kajiwara, Takeshi
Hayashi, Yuichiro
Kawakami, Yutaka
Nakajima, Takako Eguchi
机构：
[1] Chiba Canc Ctr, Clin Trial Promot Dept, Chiba, Japan
[2] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[3] St Marianna Univ, Sch Med, Dept Clin Oncol, Kawasaki, Kanagawa, Japan
[4] Natl Hosp Org Shikoku Canc Ctr, Matsuyama, Ehime, Japan
[5] Yokohama City Univ, Sch Med, Yokohama, Kanagawa, Japan
[6] Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan
[7] USC Keck Sch Med, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[8] Natl Hosp Org Shikoku Canc Ctr, Dept Gastrointestinal Med Oncol, Matsuyama, Ehime, Japan
[9] Keio Univ, Sch Med, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
352
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as the second-line treatment in patients with advanced gastric cancer
    Kadowaki, S.
    Izawa, N.
    Minashi, K.
    Nishina, T.
    Yamanaka, T.
    Muro, K.
    Sunakawa, Y.
    Hironaka, S.
    Kajiwara, T.
    Kawakami, Y.
    Nakajima, T.
    ANNALS OF ONCOLOGY, 2019, 30
  • [2] Multicenter Phase I/II Study of Nivolumab Combined with Paclitaxel Plus Ramucirumab as Second-line Treatment in Patients with Advanced Gastric Cancer
    Nakajima, Takako Eguchi
    Kadowaki, Shigenori
    Minashi, Keiko
    Nishina, Tomohiro
    Yamanaka, Takeharu
    Hayashi, Yuichiro
    Izawa, Naoki
    Muro, Kei
    Hironaka, Shuichi
    Kajiwara, Takeshi
    Kawakami, Yutaka
    CLINICAL CANCER RESEARCH, 2021, 27 (04) : 1029 - 1036
  • [3] An investigator initiated multicenter phase I/II study of paclitaxel, ramucirumab with nivolumab as the second-line treatment in patients with metastatic gastric cancer.
    Nishina, Tomohiro
    Hironaka, Shuichi
    Kadowaki, Shigenori
    Yamanaka, Takeharu
    Nakajima, Takako Eguchi
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] Phase I/II study of ramucirumab plus nivolumab in patients in second-line treatment for advanced gastric adenocarcinoma (NivoRam study).
    Hara, Hiroki
    Shoji, Hirokazu
    Takahari, Daisuke
    Esaki, Taito
    Machida, Nozomu
    Nagashima, Kengo
    Aoki, Kazunori
    Honda, Kazufumi
    Miyamoto, Takahiro
    Boku, Narikazu
    Kato, Ken
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [5] Phase I/Ib study of crenolanib with ramucirumab and paclitaxel as second-line therapy for advanced esophagogastric adenocarcinoma
    Ryan H. Moy
    Megan Greally
    Joanne F. Chou
    Jia Li
    Avni M. Desai
    Sree B. Chalasani
    Elizabeth Won
    David P. Kelsen
    David H. Ilson
    Yelena Y. Janjigian
    Marinela Capanu
    Geoffrey Y. Ku
    Cancer Chemotherapy and Pharmacology, 2022, 89 : 255 - 265
  • [6] Phase I/Ib study of crenolanib with ramucirumab and paclitaxel as second-line therapy for advanced esophagogastric adenocarcinoma
    Moy, Ryan H.
    Greally, Megan
    Chou, Joanne F.
    Li, Jia
    Desai, Avni M.
    Chalasani, Sree B.
    Won, Elizabeth
    Kelsen, David P.
    Ilson, David H.
    Janjigian, Yelena Y.
    Capanu, Marinela
    Ku, Geoffrey Y.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (02) : 255 - 265
  • [7] A phase Ib/II study of fruquintinib in combination with paclitaxel as the second-line therapy for advanced gastric cancer
    Zhang, Yang
    Wang, Zi-Xian
    Shen, Lin
    Li, Jin
    Huang, Jing
    Su, Wei-Guo
    Zhang, Dong-Sheng
    Xu, Rui-Hua
    CANCER COMMUNICATIONS, 2023, 43 (01) : 150 - 153
  • [8] Paclitaxel combined with ramucirumab as the second-line chemotherapy for elderly patients with advanced gastric cancer.
    Kusumoto, Tetsuya
    Uehara, Hideo
    Hashimoto, Kenkichi
    Fujinaka, Yoshihiko
    Yoshinaga, Keiji
    Kusumoto, Eiji
    Shinzato, Chiaki
    Sakaguchi, Yoshihisa
    Ikejiri, Koji
    Maehara, Yoshihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] Nab-paclitaxel plus ramucirumab combination therapy as second-line with advanced gastric cancer:Retrospective study
    Kashiwada, Tomomi
    Nishioka, Atsujiro
    Komiya, Kazutoshi
    Aragane, Naoko
    Kimura, Shinya
    ANNALS OF ONCOLOGY, 2019, 30 : 140 - 140
  • [10] The role of ramucirumab plus paclitaxel as second-line therapy after failure of nivolumab plus doublet chemotherapy in patients with advanced gastric cancer
    Jeon, Youngkyung
    Lim, Sung Hee
    Lee, Jeeyun
    Kang, Won Ki
    Jang, Jae Yeon
    Jeong, Sun Young
    Choi, Daeho
    Kim, Seung Tae
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2023, 14 (06) : 2346 - 2353
12345